Mark S de Souza1, Suteeraporn Pinyakorn2, Siriwat Akapirat3, Supanit Pattanachaiwit4, James L K Fletcher5, Nitiya Chomchey5, Eugene D Kroon6, Sasiwimol Ubolyam7, Nelson L Michael8, Merlin L Robb2, Praphan Phanuphak6, Jerome H Kim9, Nittaya Phanuphak6, Jintanat Ananworanich10. 1. South East Asia Research Collaboration with Hawaii (SEARCH) Thai Red Cross AIDS Research Centre, Bangkok, Thailand Cooper Human Systems, Cambridge, Massachusetts. 2. Henry M. Jackson Foundation for the Advancement of Military Medicine United States Military HIV Research Program, Bethesda, Maryland. 3. Department of Retrovirology, Armed Forces Research Institute of Medical Sciences, United States Component. 4. Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 5. South East Asia Research Collaboration with Hawaii (SEARCH). 6. South East Asia Research Collaboration with Hawaii (SEARCH) Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 7. HIV Netherlands Australia Thailand Research Collaboration, Bangkok. 8. United States Military HIV Research Program, Bethesda, Maryland Walter Reed Army Institute of Research, Silver Spring, Maryland. 9. International Vaccine Institute, Seoul, South Korea. 10. South East Asia Research Collaboration with Hawaii (SEARCH) Henry M. Jackson Foundation for the Advancement of Military Medicine United States Military HIV Research Program, Bethesda, Maryland.
Abstract
BACKGROUND: Third- and fourth-generation immunoassays (IAs) are widely used in the diagnosis of human immunodeficiency virus (HIV) infection. Antiretroviral therapy (ART) during acute HIV infection (AHI) may impact HIV-specific antibodies, with failure to develop antibody or seroreversion. We report on the ability of diagnostic tests to detect HIV-specific antibodies in Thai participants initiating ART during AHI. METHODS: Participants with detectable plasma HIV RNA but nonreactive HIV-specific immunoglobulin G, enrolled in an AHI study, were offered immediate initiation of ART. Participants were tested at initiation and at 12 and 24 weeks following treatment using standard second-, third-, and fourth-generation IAs and Western blot (WB). RESULTS: Participants (N = 234) initiating ART at a median of 19 days (range, 1-62 days) from HIV exposure demonstrated different frequencies of reactivity prior to and following 24 weeks of ART depending on the IA. Third-generation IA nonreactivity prior to ART was 48%, which decreased to 4% following ART (P < .001). Fourth-generation IA nonreactivity was 18% prior to ART and 17% following ART (P = .720). Negative WB results were observed in 89% and 12% of participants prior to and following 24 weeks of ART, respectively (P < .001). Seroreversion to nonreactivity during ART was observed to at least one of the tests in 20% of participants, with fourth-generation IA demonstrating the highest frequency (11%) of seroreversion. CONCLUSIONS: HIV-specific antibodies may fail to develop and, when detected, may decline when ART is initiated during AHI. Although fourth-generation IA was the most sensitive at detecting AHI prior to ART, third-generation IA was the most sensitive during treatment. CLINICAL TRIALS REGISTRATION: NCT00796146 and NCT00796263.
BACKGROUND: Third- and fourth-generation immunoassays (IAs) are widely used in the diagnosis of human immunodeficiency virus (HIV) infection. Antiretroviral therapy (ART) during acute HIV infection (AHI) may impact HIV-specific antibodies, with failure to develop antibody or seroreversion. We report on the ability of diagnostic tests to detect HIV-specific antibodies in Thai participants initiating ART during AHI. METHODS:Participants with detectable plasma HIV RNA but nonreactive HIV-specific immunoglobulin G, enrolled in an AHI study, were offered immediate initiation of ART. Participants were tested at initiation and at 12 and 24 weeks following treatment using standard second-, third-, and fourth-generation IAs and Western blot (WB). RESULTS:Participants (N = 234) initiating ART at a median of 19 days (range, 1-62 days) from HIV exposure demonstrated different frequencies of reactivity prior to and following 24 weeks of ART depending on the IA. Third-generation IA nonreactivity prior to ART was 48%, which decreased to 4% following ART (P < .001). Fourth-generation IA nonreactivity was 18% prior to ART and 17% following ART (P = .720). Negative WB results were observed in 89% and 12% of participants prior to and following 24 weeks of ART, respectively (P < .001). Seroreversion to nonreactivity during ART was observed to at least one of the tests in 20% of participants, with fourth-generation IA demonstrating the highest frequency (11%) of seroreversion. CONCLUSIONS:HIV-specific antibodies may fail to develop and, when detected, may decline when ART is initiated during AHI. Although fourth-generation IA was the most sensitive at detecting AHI prior to ART, third-generation IA was the most sensitive during treatment. CLINICAL TRIALS REGISTRATION: NCT00796146 and NCT00796263.
Authors: Stephanie E Cohen; Darpun Sachdev; Sulggi A Lee; Susan Scheer; Oliver Bacon; Miao-Jung Chen; Hideaki Okochi; Peter L Anderson; Mary F Kearney; Susa Coffey; Hyman Scott; Robert M Grant; Diane Havlir; Monica Gandhi Journal: Lancet HIV Date: 2018-11-29 Impact factor: 12.767
Authors: Peter D Burbelo; Richard W Price; Lars Hagberg; Hiroyu Hatano; Serena Spudich; Steven G Deeks; Magnus Gisslén Journal: J Infect Dis Date: 2018-03-13 Impact factor: 5.226
Authors: Wendy Sykes; Karin Van den Berg; Genevieve Jacobs; Adam Jauregui; Nareg Roubinian; Lubbe Wiesner; Gary Maartens; Ronel Swanevelder; Brian Custer; Michael Busch; Ute Jentsch; Edward L Murphy; Marion Vermeulen Journal: J Infect Dis Date: 2019-07-19 Impact factor: 5.226
Authors: Zaza M Ndhlovu; Samuel W Kazer; Thandeka Nkosi; Funsho Ogunshola; Daniel M Muema; Gursev Anmole; Shayda A Swann; Amber Moodley; Krista Dong; Tarylee Reddy; Mark A Brockman; Alex K Shalek; Thumbi Ndung'u; Bruce D Walker Journal: Sci Transl Med Date: 2019-05-22 Impact factor: 17.956
Authors: Brian Custer; Claire Quiner; Richard Haaland; Amy Martin; Mars Stone; Rita Reik; Whitney R Steele; Debra Kessler; Phillip C Williamson; Steven A Anderson; Alan E Williams; Henry F Raymond; Willi McFarland; William T Robinson; Sara Glick; Kwa Sey; C David Melton; Simone A Glynn; Susan L Stramer; Michael P Busch Journal: Blood Date: 2020-09-10 Impact factor: 22.113
Authors: Jessica M Fogel; Estelle Piwowar-Manning; Barbara Debevec; Tamara Walsky; Katherine Schlusser; Oliver Laeyendecker; Ethan A Wilson; Marybeth McCauley; Theresa Gamble; Gerald Tegha; Dean Soko; Johnstone Kumwenda; Mina C Hosseinipour; Ying Q Chen; Myron S Cohen; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2017-08-01 Impact factor: 3.731
Authors: Ethan Klock; George Mwinnya; Leigh Anne Eller; Reinaldo E Fernandez; Hannah Kibuuka; Sorachai Nitayaphan; Josphat Kosgei; Richard D Moore; Merlin Robb; Susan H Eshleman; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2020-05-27 Impact factor: 2.205
Authors: Joanne D Stekler; Kenneth Tapia; Janine Maenza; Claire E Stevens; George A Ure; Joshua D O'Neal; Aric Lane; James I Mullins; Robert W Coombs; Sarah Holte; Ann C Collier Journal: AIDS Res Hum Retroviruses Date: 2018-06-13 Impact factor: 2.205